Celltrion Signs Contract with Major U.S. Insurer Cigna to List 'Zymfentra'

Celltrion has signed a listing agreement for Zymfentra with the major U.S. insurer Cigna, following its successful agreements with the three largest Pharmacy Benefit Managers (PBMs) just five months after Zymfentra's launch in the U.S. With this agreement, Zymfentra prescriptions are expected to accelerate further as insurance reimbursement becomes available for Cigna subscribers.

On the 29th, Celltrion announced that it had secured a preferred drug listing agreement for Zymfentra, its autoimmune disease treatment, with Cigna Healthcare (hereafter Cigna), one of the largest insurers in the U.S. Zymfentra is the world’s only subcutaneous infliximab formulation.

Cigna is a top-ten insurer in the U.S. insurance industry, with approximately 16.1 million subscribers. It is part of the Cigna Group, which also includes Express Scripts (ESI), one of the three major PBMs. The Cigna Group has significant influence in the U.S. healthcare market, with subsidiaries including Cigna Healthcare, ESI, and specialty pharmacy Accredo.

Celltrion emphasized that securing coverage with a major insurer like Cigna, in addition to the three largest PBMs within five months of Zymfentra’s U.S. launch, is a significant achievement. Zymfentra is now listed in a total of 26 formularies, including those of Cigna and various national and regional PBMs, laying a strong foundation for the expansion of prescriptions.

Furthermore, Celltrion plans to intensify its comprehensive, targeted marketing activities to expand Zymfentra prescriptions among both healthcare providers and patients. The company is working on strengthening its network with key physicians across the U.S. and will launch Zymfentra TV and social media advertisements nationwide starting next month to raise public awareness. The goal is to achieve a market share of at least 15% in the U.S. by 2025, Zymfentra’s second year on the market.

A representative from Celltrion’s U.S. subsidiary stated, "We anticipate that our partnerships with Cigna, ESI, and others will significantly broaden the treatment options available to doctors and patients. Zymfentra offers substantial value in the U.S. inflammatory bowel disease (IBD) market as a high-quality biologic that can be conveniently self-administered at home."